SCHEMBL335088

SCHEMBL335088

NCCCCNC(=O)OCc1ccccc1

nearest known ligand 0.75

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.70
TGM2 P21980 1/20 0.66
LMNA P02545 1/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
KEAP1 Q14145 2/20 0.63
NFE2L2 Q16236 2/20 0.63
CPB1 P15086 1/20 0.59
CPB2 Q96IY4 1/20 0.59
DPP8 Q6V1X1 1/20 0.56
DPP7 Q9UHL4 1/20 0.56
FOLH1 Q04609 2/20 0.55
SLC1A3 P43003 1/20 0.54
SLC1A1 P43005 1/20 0.54
ANPEP P15144 1/20 0.54
L3MBTL1 Q9Y468 2/20 0.53
MAPT P10636 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5493238 0.98 HTT (0.68) HTTTGM2LMNASMN1; SMN2KEAP1
SCHEMBL235394 0.98 HTT (0.68) HTTTGM2LMNASMN1; SMN2KEAP1
SCHEMBL3049211 0.98 HTT (0.68) HTTTGM2LMNASMN1; SMN2KEAP1
SCHEMBL2076614 0.98 HTT (0.68) HTTTGM2LMNASMN1; SMN2KEAP1
SCHEMBL7863455 0.98 HTT (0.68) HTTTGM2LMNASMN1; SMN2KEAP1
SCHEMBL4363476 0.98 HTT (0.68) HTTTGM2LMNASMN1; SMN2KEAP1
SCHEMBL19240717 0.98 HTT (0.68) HTTTGM2LMNASMN1; SMN2KEAP1
SCHEMBL29040497 0.98 HTT (0.68) HTTTGM2LMNASMN1; SMN2KEAP1
Bicarbonate SCHEMBL10633260 0.98 HTT (0.68) HTTTGM2LMNASMN1; SMN2KEAP1
SCHEMBL29040501 0.98 HTT (0.68) HTTTGM2LMNASMN1; SMN2KEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114957176-A Human angiotensin converting enzyme inhibitor compound and synthetic method 河南中医药大学第一附属医院 2022-08-30 CN claimed
US-20250115561-A1 BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS PARION SCIENCES, INC. (US) 2025-04-10 US disclosed
EP-4469441-A1 BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS Parion Sciences, Inc. (US) 2024-12-04 EP disclosed
US-20240124484-A1 IMIDAZOTHIENOPYRIDINE COMPOUNDS AND METHODS OF USE ZYMEWORKS BC INC (CA) 2024-04-18 US disclosed
WO-2023146892-A1 BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS PARION SCIENCES, INC. (US) 2023-08-03 WO disclosed
CN-114957176-A Human angiotensin converting enzyme inhibitor compound and synthetic method 河南中医药大学第一附属医院 2022-08-30 CN disclosed
US-20220213121-A1 SUBSTITUTED 1,2,3,3a,4,5,7,9,13,13a-DECAHYDROPYRIDO[1',2':4,5]PYRAZINO[1,2-a]PYRROLO[1,2-c]PYRIMIDINES HAVING HIV INTEGRASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2022-07-07 US disclosed
US-11203597-B2 Crystalline spirocyclic compound, a dosage form containing, a method for using in treatment of disease, and a method for recrystallizing ALTAVANT SCIENCES GMBH (CH) 2021-12-21 US disclosed
US-20200148681-A1 CRYSTALLINE SPIROCYCLIC COMPOUND, A DOSAGE FORM CONTAINING, A METHOD FOR USING IN TREATMENT OF DISEASE, AND A METHOD FOR RECRYSTALLIZING ROIVANT SCIENCES GMBH (CH) 2020-05-14 US disclosed
US-20190152990-A1 POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2019-05-23 US disclosed
US-4866087-A HYPOTENSIVE AGENTS MERCK & CO., INC. (US) 1989-09-12 US disclosed
EP-0117501-B1 A PROCESS FOR THE PREPARATION OF 1,5-DIPROTECTED-1,5,10-TRIAZADECANE, INTERMEDIATES THEREOF AND THEIR PREPARATION MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) 1988-04-06 EP disclosed
US-4665087-A ANGIOTENSIN-CONVERTING ENZYME INHIBITORS CIBA-GEIGY CORPORATION (US) 1987-05-12 US disclosed
US-4518532-A ANTITIMOR ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) 1985-05-21 US disclosed
US-4518802-A IMMUNOSTIMULANT ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) 1985-05-21 US disclosed
EP-0117501-A1 A process for the preparation of 1,5-diprotected-1,5,10-triazadecane, intermediates thereof and their preparation MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) 1984-09-05 EP disclosed
US-4430346-A N-(4-(3-AMINOPROPYL)AMINOBUTYL)-2-(CS)-7-GUANIDINO-3 -HYDROXYHEPTANAMIDE)-2-HYDROXYETHANAMIDE, ESTERS, AMIDATION ACID CATALYST BRISTOL-MYERS COMPANY (US) 1984-02-07 US disclosed
US-4402969-A UREA ANALOGS OF DIPEPTIDES MERCK & CO., INC. (US) 1983-09-06 US disclosed
US-4387238-A ANTIINFLAMMATORY, HYPOTENSIVE AGENTS, ENZYME INHIBITORS, ANTISPASMODIC AGENTS TAISHO PHARMACEUTICAL CO., LTD. (JP) 1983-06-07 US disclosed
EP-0061684-A1 Urea compounds as antihypertensives MERCK & CO. INC. (US) 1982-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250115561-A1 BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS CFTR, SCNN1B, SCNN1G HTT 1451/4885TGM2 3851/4885LMNA 1712/4885
US-20220213121-A1 SUBSTITUTED 1,2,3,3a,4,5,7,9,13,13a-DECAHYDROPYRIDO[1',2':4,5]PYRAZINO[1,2-a]PYRROLO[1,2-c]PYRIMIDINES HAVING HIV INTEGRASE INHIBITORY ACTIVITY TYMP, TYMS, POLA1 HTT 3131/4885TGM2 4060/4885LMNA 2002/4885
US-11203597-B2 Crystalline spirocyclic compound, a dosage form containing, a method for using in treatment of disease, and a method for recrystallizing PKD2, PKD1, REN HTT 929/4885TGM2 2536/4885LMNA 645/4885
US-20200148681-A1 CRYSTALLINE SPIROCYCLIC COMPOUND, A DOSAGE FORM CONTAINING, A METHOD FOR USING IN TREATMENT OF DISEASE, AND A METHOD FOR RECRYSTALLIZING PKD2, PKD1, REN HTT 929/4885TGM2 2536/4885LMNA 645/4885
US-20190152990-A1 POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY NR4A1, NR4A3, NCOA4 HTT 2191/4885TGM2 3514/4885LMNA 4634/4885
US-20240124484-A1 IMIDAZOTHIENOPYRIDINE COMPOUNDS AND METHODS OF USE DHFR, RARS2, DPYD HTT 2803/4885TGM2 3138/4885LMNA 3432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.